AU
UK
CA
NZ
IND
US
Last update at 2026-06-12T20:00:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
Zymeworks Provides Corporate Update and Reports First Quarter 2025 Financial Results
Thu 08 May 25, 08:05 PMZymeworks Presents New Data from Multiple Development Programs at 2025 AACR Annual Meeting
Fri 25 Apr 25, 05:00 PMZymeworks Appoints Dr. Sabeen Mekan as Senior Vice President, Clinical Development
Mon 21 Apr 25, 10:00 AMZymeworks Inc. (ZYME): Among Stocks Insiders Bought in April After Trump’s Tariff Rollout
Wed 09 Apr 25, 02:13 PM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | 135.23M | -212.35900M | -180.12300M | -146.01900M | -34.38500M |
| Minority interest | - | - | - | - | - |
| Net income | 124.34M | -211.84300M | -180.55200M | -145.43700M | -36.55600M |
| Selling general administrative | 73.36M | 42.56M | 57.88M | 64.18M | 29.46M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 412.48M | 26.68M | 38.95M | 29.54M | 53.02M |
| Reconciled depreciation | 12.00M | 12.22M | 10.28M | 7.33M | 3.63M |
| Ebit | 118.52M | -225.21600M | -197.74700M | -151.30100M | -36.75700M |
| Ebitda | 130.53M | -215.63300M | -187.46800M | -149.76500M | -33.12700M |
| Depreciation and amortization | 12.00M | 9.58M | 10.28M | 1.54M | 3.63M |
| Non operating income net other | - | 1.31M | 7.34M | 5.28M | -1.09200M |
| Operating income | 130.53M | -215.63300M | -187.46800M | -151.30100M | -33.12700M |
| Other operating expenses | 281.95M | 242.31M | 226.42M | 180.08M | 86.15M |
| Interest expense | 3.60M | 12.86M | 17.62M | 11.08M | 0.17M |
| Tax provision | 10.89M | -0.51600M | 0.43M | -0.58200M | 2.17M |
| Interest income | 3.60M | 2.51M | 5.70M | 6.02M | 2.64M |
| Net interest income | 3.60M | 2.51M | 5.70M | 6.02M | 2.47M |
| Extraordinary items | - | - | - | -0.01000M | -0.00200M |
| Non recurring | - | - | - | 0.77M | - |
| Other items | - | - | - | - | - |
| Income tax expense | 10.89M | -0.51600M | 0.43M | -0.58200M | 2.17M |
| Total revenue | 412.48M | 26.68M | 38.95M | 29.54M | 53.02M |
| Total operating expenses | 281.95M | 242.31M | 226.42M | 180.08M | 86.15M |
| Cost of revenue | - | - | - | 115.90M | 56.93M |
| Total other income expense net | 4.71M | 3.27M | 7.34M | 5.28M | -1.25800M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | 124.34M | -211.84300M | -180.55200M | -145.43700M | -36.55600M |
| Net income applicable to common shares | 124.34M | -211.84300M | -180.55200M | -145.43700M | -36.55600M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Total assets | 463.09M | 580.88M | 648.73M | 389.13M | 538.38M |
| Intangible assets | 4.58M | 25.28M | 26.38M | 21.47M | 22.93M |
| Earning assets | - | - | - | - | - |
| Other current assets | 18.86M | 19.12M | 19.07M | 20.00M | 13.43M |
| Total liab | 124.32M | 116.07M | 155.77M | 140.04M | 128.45M |
| Total stockholder equity | 338768.00M | 464.81M | 492.96M | 249.09M | 409.92M |
| Deferred long term liab | - | - | 17.64M | 34.51M | 34.12M |
| Other current liab | 49.71M | 41.59M | 82.09M | 7.78M | 39.30M |
| Common stock | 1015618.00M | 1006.57M | 906.76M | 741.15M | 724.22M |
| Capital stock | 1023.81M | 1006.57M | 906.76M | 741.15M | 724.22M |
| Retained earnings | -830335.00000M | -677.43700M | -558.76300M | -683.10400M | -471.26100M |
| Other liab | - | - | 35.35M | 37.26M | 36.98M |
| Good will | 12.02M | 12.02M | 12.02M | 12.02M | 12.02M |
| Other assets | -162477.36000M | - | 34.71M | 34.40M | 65.81M |
| Cash | 66103.00M | 157.56M | 400.91M | 201.87M | 242.04M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 88.29M | 55.76M | 95.62M | 71.85M | 85.67M |
| Current deferred revenue | 25.59M | 3.70M | 2.35M | 57.59M | 37.41M |
| Net debt | -47625.00000M | -130.83500M | -372.79900M | -169.53400M | -233.39200M |
| Short term debt | 2.74M | 4.26M | 3.32M | 1.31M | 2.71M |
| Short long term debt | - | - | - | - | - |
| Short long term debt total | 18478.00M | 26.72M | 28.11M | 32.33M | 8.64M |
| Other stockholder equity | 160437.00M | 142.27M | 151.61M | 197.71M | 163.62M |
| Property plant equipment | - | - | 47.65M | 22.78M | 12.19M |
| Total current assets | 300.45M | 412.93M | 544.71M | 288.22M | 455.08M |
| Long term investments | 98.43M | 82.15M | 0.89M | 0.89M | 25.92M |
| Net tangible assets | - | - | 472.19M | 215.61M | 374.98M |
| Short term investments | 159.67M | 216.77M | 91.32M | 50.74M | 184.32M |
| Net receivables | 55.81M | 19.48M | 33.40M | 15.61M | 15.29M |
| Long term debt | - | - | - | - | - |
| Inventory | - | 0.00000M | - | - | - |
| Accounts payable | 3.90M | 6.21M | 7.86M | 5.17M | 6.24M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -6952.00000M | -6.60300M | -6.65900M | -6.65900M | -6.65900M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | 741.15M | 724.22M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | -683.10400M | -471.26100M |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 8.92M | 7.35M | 15.74M | 13.70M | 3.10M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 162.64M | 167.95M | 104.02M | 100.91M | 83.30M |
| Capital lease obligations | 18.51M | 26.72M | 28.11M | 41.23M | 8.64M |
| Long term debt total | - | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -53.84900M | 157.88M | -37.17500M | -11.71400M | -105.62600M |
| Change to liabilities | 26.48M | 16.48M | 7.62M | 21.27M | 3.82M |
| Total cashflows from investing activities | -53.84900M | 144.60M | -43.44000M | -25.59200M | -109.04600M |
| Net borrowings | -0.01400M | -0.01700M | -0.04100M | -0.01600M | -0.01100M |
| Total cash from financing activities | 108.58M | 8.01M | 308.98M | 193.66M | 91.43M |
| Change to operating activities | -5.79500M | -15.81800M | -4.65900M | -9.47500M | -0.25100M |
| Net income | 124.34M | -211.84300M | -180.55200M | -145.43700M | -36.55600M |
| Change in cash | 199.04M | -40.16900M | 113.58M | 86.25M | 6.26M |
| Begin period cash flow | 201.87M | 242.04M | 128.45M | 42.20M | 35.95M |
| End period cash flow | 400.91M | 201.87M | 242.04M | 128.45M | 42.20M |
| Total cash from operating activities | 144.11M | -192.45100M | -151.40300M | -81.85300M | 24.18M |
| Issuance of capital stock | 107.53M | 0.00000M | 300.91M | 188.23M | 90.75M |
| Depreciation | 12.00M | 9.58M | 10.28M | 7.33M | 3.63M |
| Other cashflows from investing activities | - | -0.88100M | -1.95500M | -7.55600M | -2.61700M |
| Dividends paid | - | - | -1.11100M | -0.59800M | - |
| Change to inventory | - | - | - | -9.77400M | -0.11100M |
| Change to account receivables | -17.50900M | -0.26600M | -13.10700M | -1.82800M | -0.11900M |
| Sale purchase of stock | 1.40M | 2.07M | 1.11M | 0.60M | 91.43M |
| Other cashflows from financing activities | -0.34100M | 5.96M | 8.11M | 5.45M | 0.69M |
| Change to netincome | 3.75M | 9.20M | 28.93M | 49.54M | 16.94M |
| Capital expenditures | 13.12M | 13.29M | 6.26M | 13.88M | 3.42M |
| Change receivables | - | -0.26600M | -13.10700M | -1.82800M | -0.11900M |
| Cash flows other operating | - | -12.55400M | -1.80600M | -10.82800M | 36.46M |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | -39.84400M | 114.14M | 86.22M | 6.56M |
| Change in working capital | 4.01M | 0.39M | -10.14800M | 6.44M | 39.92M |
| Stock based compensation | 4.01M | 10.76M | 29.12M | 49.00M | 13.44M |
| Other non cash items | -2.20600M | -0.38700M | -0.36400M | 1.54M | 3.75M |
| Free cash flow | 130.98M | -205.73600M | -157.66800M | -95.73100M | 20.76M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| ZYME Zymeworks Inc. Common Stock |
-0.085 0.37% | 22.88 | - | - | 8.74 | 2.51 | 6.09 | 0.34 |
| NVO Novo Nordisk A/S |
-0.08 0.18% | 43.88 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| NONOF Novo Nordisk A/S |
1.99 4.74% | 44.00 | 41.06 | 31.25 | 2.08 | 33.11 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-0.115 0.03% | 444.93 | 29.67 | 24.33 | 10.38 | 5.83 | 9.33 | 20.00 |
| REGN Regeneron Pharmaceuticals Inc |
0.66 0.11% | 612.14 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
Zymeworks Inc., a clinical-stage biotechnology company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer, and autoimmune and inflammatory diseases (AIID). Its therapeutic platforms and fully integrated drug development engine provides the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutic candidates. The company's platforms include Azymetric multispecific antibody platform; Drug Conjugate platform includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies that enable the selective modulation of recruited cytotoxic immune cells for various therapeutic applications; and ProTECT, a tumor-specific immune co-stimulation platform. Its lead product candidate consists of zanidatamab, a novel bispecific antibody that targets human epidermal growth factor receptor 2 HER2 that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. In addition, the company develops a pipeline of preclinical product candidates. It has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.
108 Patriot Drive, Middletown, DE, United States, 19709
| Name | Title | Year Born |
|---|---|---|
| Mr. Neil A. Klompas C.A., CPA, CA, CPA | Pres & COO | 1972 |
| Dr. Ali Tehrani Ph.D. | Advisor | 1972 |
| Dr. Neil Josephson M.D. | Chief Medical Officer | 1961 |
| Mr. Kenneth H. Galbraith C.A. | CEO & Chairman | 1963 |
| Dr. Christopher Astle Ph.D. | Sr. VP & CFO | 1980 |
| Dr. Paul Moore Ph.D. | Chief Scientific Officer | NA |
| Jack W. Spinks | Mang. of Investor Relations | NA |
| Mr. Daniel Dex J.D., Ph.D. | VP of Legal & Corp. Sec. | NA |
| Mr. Mark Hollywood | Sr. VP of Technical & Manufacturing Operations | 1970 |
| Dr. David Poon Ph.D. | VP of Bus. Devel. and Alliance Management | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Please wait processing your request...